Bicentric Clinical Investigation to Assess Safety and Performance of LuxBoost IOL
Condition(s) studied
Investigational drug(s) / intervention(s)
LuxBoost IOL: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
LuxGood IOL: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
Study summary
The study purpose is to demonstrate safety and performance of bilateral implantation of LuxBoost intraocular lenses compared with the LuxGood Monofocal lens.
Eligibility
Primary outcome measure(s)
- Best corrected distance visual acuity (CDVA) — 4/6 months after surgery
To demonstrate the non-inferiority of LuxBoost IOL compared with the LuxGood monofocal control lens in terms of best corrected distance visual acuity (CDVA) by means of statistical significance.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Clinique Honore Cave | Montauban | France | Recruiting |
| West Ophta | Rennes | France | Recruiting |
More Cutting Edge SAS trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06258707 on ClinicalTrials.gov ↗ ← All trials in France